JP6761852B2 - がん治療 - Google Patents

がん治療 Download PDF

Info

Publication number
JP6761852B2
JP6761852B2 JP2018511527A JP2018511527A JP6761852B2 JP 6761852 B2 JP6761852 B2 JP 6761852B2 JP 2018511527 A JP2018511527 A JP 2018511527A JP 2018511527 A JP2018511527 A JP 2018511527A JP 6761852 B2 JP6761852 B2 JP 6761852B2
Authority
JP
Japan
Prior art keywords
cancer
nuc
treatment
patient
cycle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2018511527A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018515618A (ja
JP2018515618A5 (enExample
Inventor
グリフィス ヒュー
グリフィス ヒュー
マクギガン クリス
マクギガン クリス
ペッパー クリス
ペッパー クリス
Original Assignee
ニューカナ パブリック リミテッド カンパニー
ニューカナ パブリック リミテッド カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53276184&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6761852(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ニューカナ パブリック リミテッド カンパニー, ニューカナ パブリック リミテッド カンパニー filed Critical ニューカナ パブリック リミテッド カンパニー
Publication of JP2018515618A publication Critical patent/JP2018515618A/ja
Publication of JP2018515618A5 publication Critical patent/JP2018515618A5/ja
Application granted granted Critical
Publication of JP6761852B2 publication Critical patent/JP6761852B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57595—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving intracellular compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2018511527A 2015-05-14 2015-05-14 がん治療 Expired - Fee Related JP6761852B2 (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB2015/051438 WO2016181093A1 (en) 2015-05-14 2015-05-14 Cancer treatments

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019040537A Division JP6810763B2 (ja) 2019-03-06 2019-03-06 がん治療

Publications (3)

Publication Number Publication Date
JP2018515618A JP2018515618A (ja) 2018-06-14
JP2018515618A5 JP2018515618A5 (enExample) 2018-07-26
JP6761852B2 true JP6761852B2 (ja) 2020-09-30

Family

ID=53276184

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018511527A Expired - Fee Related JP6761852B2 (ja) 2015-05-14 2015-05-14 がん治療

Country Status (26)

Country Link
US (3) US20180289733A1 (enExample)
EP (2) EP3415149A1 (enExample)
JP (1) JP6761852B2 (enExample)
KR (1) KR20180021697A (enExample)
CN (2) CN115837028A (enExample)
AU (2) AU2015394135B2 (enExample)
BR (1) BR112017024461B1 (enExample)
CA (1) CA2985540C (enExample)
CY (1) CY1120516T1 (enExample)
DK (1) DK3197456T3 (enExample)
EA (1) EA201792509A1 (enExample)
ES (1) ES2668377T3 (enExample)
HR (1) HRP20180762T1 (enExample)
HU (1) HUE038541T2 (enExample)
IL (1) IL255591B (enExample)
LT (1) LT3197456T (enExample)
MX (2) MX374946B (enExample)
MY (1) MY192081A (enExample)
PH (1) PH12017502086B1 (enExample)
PL (1) PL3197456T3 (enExample)
PT (1) PT3197456T (enExample)
RS (1) RS57371B1 (enExample)
SI (1) SI3197456T1 (enExample)
SM (1) SMT201800303T1 (enExample)
TR (1) TR201806642T4 (enExample)
WO (1) WO2016181093A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
DK3447061T3 (da) 2011-03-01 2022-01-03 NuCana plc Farmaceutisk formulering omfattende et phosphoramidatderivat af 5-fluor-2'-deoxyuridin til anvendelse i cancerbehandling
HUE044605T2 (hu) 2012-11-16 2019-11-28 Univ College Cardiff Consultants Ltd RP/SP gemcitabin-[fenil-(benziloxi-L-alaninil)]-foszfát keveréke
KR102563040B1 (ko) 2014-06-25 2023-08-02 뉴카나 피엘씨 젬시타빈 전구 약물
PT3119794T (pt) 2014-06-25 2018-01-15 Nucana Biomed Ltd Formulação que compreende um pró-fármaco de gemcitabina
GB201417644D0 (en) 2014-10-06 2014-11-19 Nucana Biomed Ltd Method of separating phosphate diastereoisomers
CN111909231B (zh) 2014-11-28 2025-10-17 努卡那有限公司 作为抗癌化合物的新的2’和/或5’-氨基酸酯氨基磷酸酯3’-脱氧腺苷衍生物
EP3353201B1 (en) 2015-09-25 2021-09-08 F. Hoffmann-La Roche AG Recombinant immunoglobulin heavy chains comprising a sortase conjugation loop and conjugates thereof
CA2994502C (en) 2015-10-05 2023-08-01 NuCana plc Combination therapy comprising nuc-1031 and carboplatin for cancer treatment
SMT202100665T1 (it) 2015-12-11 2022-03-21 NuCana plc Sintesi diastereoselettiva di derivati di fosfato e del profarmaco di gemcitabina nuc-1031
GB201522771D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Crystalline form of a phosphate derivative
WO2017109444A1 (en) * 2015-12-23 2017-06-29 Nucana Biomed Limited Combination therapy
AU2016375861B2 (en) * 2015-12-23 2021-12-23 NuCana plc Combination therapy
GB201609600D0 (en) * 2016-06-01 2016-07-13 Nucuna Biomed Ltd Cancer treatments
GB201709471D0 (en) 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
GB201713916D0 (en) * 2017-08-30 2017-10-11 Nucana Biomed Ltd Treatment regimens
WO2020077353A2 (en) * 2018-10-12 2020-04-16 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for reducing cancer stem cells
CN117462555B (zh) * 2021-01-31 2025-12-30 兰州大学 6-巯基鸟嘌呤在制备预防和/或治疗酒精性胃溃疡药物中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0317009D0 (en) * 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
CN104586832B (zh) * 2007-09-10 2018-02-16 北京强新生物科技有限公司 用于癌症治疗的组合物和方法
EP2274617A4 (en) * 2008-04-10 2011-11-09 Massachusetts Inst Technology METHOD OF DETECTING AND USING MEDIUM-TREATMENT AID ON CANCER STEM CELLS

Also Published As

Publication number Publication date
BR112017024461B1 (pt) 2023-04-04
AU2015394135B2 (en) 2021-09-16
MX390506B (es) 2025-03-20
EP3415149A1 (en) 2018-12-19
EP3197456B2 (en) 2023-10-11
EP3197456B1 (en) 2018-04-04
HRP20180762T1 (hr) 2018-08-24
PH12017502086B1 (en) 2022-12-09
EP3197456A1 (en) 2017-08-02
MX2020009154A (es) 2022-03-08
MX2017014544A (es) 2018-09-26
ES2668377T3 (es) 2018-05-17
DK3197456T3 (en) 2018-06-06
AU2015394135A1 (en) 2017-12-14
US20180289733A1 (en) 2018-10-11
IL255591B (en) 2021-10-31
HUE038541T2 (hu) 2018-10-29
JP2018515618A (ja) 2018-06-14
US20230226092A1 (en) 2023-07-20
CA2985540C (en) 2021-08-24
EA201792509A1 (ru) 2018-05-31
CA2985540A1 (en) 2016-11-17
CY1120516T1 (el) 2019-07-10
CN107835687A (zh) 2018-03-23
MX374946B (es) 2025-03-06
PL3197456T3 (pl) 2018-09-28
BR112017024461A2 (pt) 2018-07-24
AU2021277614A1 (en) 2021-12-23
PT3197456T (pt) 2018-05-22
SMT201800303T1 (it) 2018-07-17
CN115837028A (zh) 2023-03-24
MY192081A (en) 2022-07-26
US20210100825A1 (en) 2021-04-08
SI3197456T1 (en) 2018-08-31
RS57371B1 (sr) 2018-08-31
IL255591A (en) 2018-01-31
PH12017502086A1 (en) 2018-04-30
WO2016181093A1 (en) 2016-11-17
TR201806642T4 (tr) 2018-06-21
LT3197456T (lt) 2018-07-10
KR20180021697A (ko) 2018-03-05

Similar Documents

Publication Publication Date Title
US20230226092A1 (en) Cancer treatments based on gemcitabine prodrugs
JP7367910B2 (ja) がんの処置
EP2882454B1 (en) Combination therapy for the treatment of glioblastoma
MX2014010591A (es) Terapia combinada para el tratamiento de cancer de ovario.
JP2024527087A (ja) スピロノラクトン及びアシルフルベンの組み合わせによるがんの処置
CN110840892A (zh) 酪氨酸激酶抑制剂与cdk4/6抑制剂联合在制备预防或治疗肿瘤疾病的药物中的用途
JP6810763B2 (ja) がん治療
HK1261423A1 (en) Cancer treatments
EA040796B1 (ru) Лечение рака
HK1237283B (en) Cancer treatments
HK1237283A1 (en) Cancer treatments

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180511

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180511

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20180511

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20180530

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180612

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180911

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20181106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190308

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200702

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200716

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200907

R150 Certificate of patent or registration of utility model

Ref document number: 6761852

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees